A sound wave that could expose hidden pancreatic cancer?

NCT ID NCT06157671

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing a new, noninvasive method called LINFU® that uses low-intensity ultrasound to stimulate the pancreas, helping to collect pancreatic juice for analysis. The goal is to see if this approach can detect early, asymptomatic pancreatic cancer and precancerous lesions better than current screening methods. The study enrolls 1,000 people at high risk for pancreatic cancer due to factors like smoking, diabetes, or family history. If it works, this could lead to a safer, more effective way to catch this deadly disease early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas) followed by analysis of pancreatic juice
What this could lead to
If successful, this could lead to a noninvasive screening tool that catches pancreatic cancer early, when it's more treatable, potentially saving lives.
What could go wrong
This is an early-stage registry study, so the method may not prove more effective than current screening tests. It also requires analysis of pancreatic juice, which may be complex and not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Manhattan Endoscopy Center

    New York, New York, 10017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.